Clover Corporation Limited · ASX:CLV
Clover — Shareholder Meeting (November 2017)
16 slides from Clover's shareholder meeting presentation, Nov 23, 2017
Slide 1: Chairman's Address
CLOVER CORPORATION LIMITED ABN 85 003 622 866 CHAIRMAN’S ADDRESS For personal use only I am pleased to inform shareholders that Clover Corporation has delivered a strong result for the last financial year as management continues to successfully implement the company’s strategic plan. Reported net pr
Slide 2: Chairman's Address (continued): Dividend and Outlook
commercialising these opportunities, however we are encouraged by the collaborative engagement to date. Our underlying infant formula business in this region has shown consistent growth. Dividend For personal use only Based on the performance of Clover in FY17 the Directors have declared a fully fra
Slide 3: Managing Director's Report 12 Months to 31 July 2017
For personal use only Managing Director’s Report 12 Months to 31 July 2017 Clover Corporation Presentation Peter Davey- Managing Director & CEO 24 November 2017
Slide 4: Vision and Mission Statement
For personal use only Vision and Mission Statement Vision To optimise the health and development of adults, infants and children. Mission To deliver science based bioactives which provide health benefits to the adults, infants and children 1
Slide 5: Full Year Performance Highlights
Full Year Performance Highlights For personal use only Total Revenue $47.9m New products released to develop additional market up 12% driven by segments in Sports improved demand; highest Nutrition ever recorded revenue Inventory at $18.8m up Net Profit $3.6m up 33% on prior year to meet 64% on
Slide 6: Market Update
For personal use only Market Update Market changes Outcomes for Clover New Chinese infant formula regulations Regulated Chinese infant formula industry requiring manufacturers to hold a CFDA and increased quality controls position license by January 2018 Clover as a premium supplier. Many of 3
Slide 7: Full Year Results 2017
For personal use only Full Year Results 2017
Slide 8: Full Year 2017 Results
For personal use only Full Year 2017 Results AUD million 4E Reported 4E Reported 11.5% year on year revenue 31 Jul 2017 31 Jul 2016 growth Revenue $47.9 $42.9 Increased sales across all EBITDA $6.1 $3.3 markets EBIT $5.5 $2.8 EBIT $5.5m (PY $2.8m) NPBT $5.0 $3.1 NPBT of $5.0m includes Tax ($
Slide 9: Balance Sheet July 2017
Balance Sheet 31 July 2017 For personal use only AUD million Reported Reported Movement 31 July 2017 31 July 2016 Cash balance strong $5.9m Cash $5.9 $8.2 2.3 Trade $12.1 $10.9 1.2 Trade receivables Receivables reflect the Inventories $18.8 $13.6 5.2 increased sales activity Total Current
Slide 10: Sales by Geography & Product
For personal use only Sales by Geography & Product Sales across all regions Encapsulated Tuna oil have grown during 2017 leads sales revenue with encapsulated Algal oils and European and American other oils represented in markets provide new other products opportunities FY 2017 Geographic FY 2
Slide 11: An Update on Growth Platforms
For personal use only An Update on Growth Platforms Infant Market formula Development customers Product Development 6
Slide 12: Growth Platform: Market Development – Infant Formula
For personal use only Growth Platform Market Infant formula Development customer s Infant formula provides further growth Product Development The Chinese regulators changed rulings during 2017. Initially they proposed banning ‘grey imports’ (called CBEC) closing the channel to market for many infa
Slide 13: Growth Platform: Products for New Segments
Market Infant formula For personal use only Development customers Growth Platform Product Development Products for new segments Clover’s Hypoallergenic DHA product is now being purchased and used in infant formula applications A new highly concentrated DHA product which delivers 60% oil in a pow
Slide 14: New Markets Development
For personal use only Growth Platform Market Development Infant formula customers New markets development Product Development Clover has aligned with distributors across the USA, Europe & Asia, providing market access and the capability to service new customer opportunities To generate a presenc
Slide 15: FY2018 Outlook & Priorities
For personal use only FY2018 Outlook & Priorities First half FY2018 sales are in line with second half 2017, assisted by pipeline fill in the China CBEC market, however the China region continues to be susceptible to unexpected regulatory change Further market development achieved through a spec
Slide 16: Disclaimer
For personal use only Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s